BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moser T, Akgün K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmun Rev 2020;19:102647. [PMID: 32801039 DOI: 10.1016/j.autrev.2020.102647] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Gadani SP, Kornberg MD. DICAM, a molecular passport for TH17 cell entry into the brain. Sci Transl Med 2022;14:eabm7204. [PMID: 34985968 DOI: 10.1126/scitranslmed.abm7204] [Reference Citation Analysis]
2 Baker D, Hadjicharalambous C, Gnanapavan S, Giovannoni G. Can rheumatologists stop causing demyelinating disease? Mult Scler Relat Disord 2021;53:103057. [PMID: 34126373 DOI: 10.1016/j.msard.2021.103057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
4 Moser T, Hoepner L, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J. Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis. Cells 2021;10:3116. [PMID: 34831335 DOI: 10.3390/cells10113116] [Reference Citation Analysis]
5 Basta F, Möckel T, Petersohn J, Meineck M, Triantafyllias K, Engel S, Weinmann A, Luessi F, Weinmann-Menke J, Schwarting A. The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis. Autoimmun Rev 2021;20:102802. [PMID: 33727153 DOI: 10.1016/j.autrev.2021.102802] [Reference Citation Analysis]
6 Han J, Zhuang W, Feng W, Dong F, Hua F, Yao R, Qu X. The circular RNA circINPP4B acts as a sponge of miR-30a to regulate Th17 cell differentiation during progression of experimental autoimmune encephalomyelitis. Cell Mol Immunol 2021. [PMID: 34363030 DOI: 10.1038/s41423-021-00748-y] [Reference Citation Analysis]
7 Takeuchi T, Yoshida H, Tanaka S. Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmun Rev 2021;20:102884. [PMID: 34229044 DOI: 10.1016/j.autrev.2021.102884] [Reference Citation Analysis]
8 Bellucci G, Rinaldi V, Buscarinu MC, Reniè R, Bigi R, Pellicciari G, Morena E, Romano C, Marrone A, Mechelli R, Salvetti M, Ristori G. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Front Immunol 2021;12:755333. [PMID: 34646278 DOI: 10.3389/fimmu.2021.755333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Alam MS, Otsuka S, Wong N, Abbasi A, Gaida MM, Fan Y, Meerzaman D, Ashwell JD. TNF plays a crucial role in inflammation by signaling via T cell TNFR2. Proc Natl Acad Sci U S A 2021;118:e2109972118. [PMID: 34873037 DOI: 10.1073/pnas.2109972118] [Reference Citation Analysis]
10 Clark M, Kroger CJ, Ke Q, Tisch RM. The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes. Front Immunol 2020;11:615371. [PMID: 33603744 DOI: 10.3389/fimmu.2020.615371] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Wang LT, Liu KJ, Sytwu HK, Yen ML, Yen BL. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Transl Med 2021;10:1288-303. [PMID: 34008922 DOI: 10.1002/sctm.21-0021] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol 2020;7:2199-212. [PMID: 33002321 DOI: 10.1002/acn3.51206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
13 Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Front Cell Neurosci 2021;15:716747. [PMID: 34381337 DOI: 10.3389/fncel.2021.716747] [Reference Citation Analysis]
14 Liu H, Yang X, Yang J, Yuan Y, Wang Y, Zhang R, Xiong H, Xu Y. IL-17 Inhibits Oligodendrocyte Progenitor Cell Proliferation and Differentiation by Increasing K+ Channel Kv1.3. Front Cell Neurosci 2021;15:679413. [PMID: 34239419 DOI: 10.3389/fncel.2021.679413] [Reference Citation Analysis]
15 Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
16 Mosure SA, Solt LA. Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity. Immunometabolism 2021;3:e210006. [PMID: 33614166 DOI: 10.20900/immunometab20210006] [Reference Citation Analysis]
17 Xu G, Chen S, Dong Y, Xiao L. Th17/1-Biased Inflammatory Environment Involved in the Response of Epithelial Cells to Antigen Stimuli in Nasal Polyps. J Immunol Res 2021;2021:5531606. [PMID: 34222494 DOI: 10.1155/2021/5531606] [Reference Citation Analysis]
18 Dobreanu M, Manu DR, Mănescu IB, Gabor MR, Huţanu A, Bărcuţean L, Bălaşa R. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An In Vitro Study. Front Immunol 2021;12:743010. [PMID: 34970256 DOI: 10.3389/fimmu.2021.743010] [Reference Citation Analysis]
19 Dominguez-Mozo MI, Perez-Perez S, Villarrubia N, Costa-Frossard L, Fernandez-Velasco JI, Ortega-Madueño I, Garcia-Martinez MA, Garcia-Calvo E, Estevez H, Luque Garcia JL, Torrejon MJ, Arroyo R, Villar LM, Alvarez-Lafuente R. Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. Cells 2021;10:119. [PMID: 33435197 DOI: 10.3390/cells10010119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Melnikov M, Pashenkov M, Boyko A. Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential? Int J Mol Sci 2021;22:5313. [PMID: 34070011 DOI: 10.3390/ijms22105313] [Reference Citation Analysis]
21 Zhang R, Liu J, Xu B, Wu Y, Liang S, Yuan Q. Cornuside alleviates experimental autoimmune encephalomyelitis by inhibiting Th17 cell infiltration into the central nervous system. J Zhejiang Univ Sci B 2021;22:421-30. [PMID: 33973423 DOI: 10.1631/jzus.B2000771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhou R, Li H, Yang H, Jiang F, Cai H, Li J, Chen S, Fang L, Yin J, Zeng Q. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis. Mult Scler Relat Disord 2021;58:103446. [PMID: 34929454 DOI: 10.1016/j.msard.2021.103446] [Reference Citation Analysis]
23 Melnikov MV, Sviridova AA, Solodova TV, Lopatina AV, Pashenkov MV, Boyko AN. [Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:82-9. [PMID: 34387452 DOI: 10.17116/jnevro202112107282] [Reference Citation Analysis]
24 Dworsky-Fried Z, Chadwick CI, Kerr BJ, Taylor AMW. Multiple Sclerosis and the Endogenous Opioid System. Front Neurosci 2021;15:741503. [PMID: 34602975 DOI: 10.3389/fnins.2021.741503] [Reference Citation Analysis]
25 Miljković Đ, Jevtić B, Stojanović I, Dimitrijević M. ILC3, a Central Innate Immune Component of the Gut-Brain Axis in Multiple Sclerosis. Front Immunol 2021;12:657622. [PMID: 33912185 DOI: 10.3389/fimmu.2021.657622] [Reference Citation Analysis]
26 Melnikov M, Sviridova A, Rogovskii V, Oleskin A, Boziki M, Bakirtzis C, Kesidou E, Grigoriadis N, Boykо A. Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy. Mult Scler Relat Disord 2021;51:102888. [PMID: 33756440 DOI: 10.1016/j.msard.2021.102888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Borgonetti V, Coppi E, Galeotti N. Targeting the RNA-Binding Protein HuR as Potential Thera-Peutic Approach for Neurological Disorders: Focus on Amyo-Trophic Lateral Sclerosis (ALS), Spinal Muscle Atrophy (SMA) and Multiple Sclerosis. Int J Mol Sci 2021;22:10394. [PMID: 34638733 DOI: 10.3390/ijms221910394] [Reference Citation Analysis]
28 Wang G, Su Z, Li H, Xiao L, Li C, Lian G. The role of metabolism in Th17 cell differentiation and autoimmune diseases. Int Immunopharmacol 2021;103:108450. [PMID: 34954561 DOI: 10.1016/j.intimp.2021.108450] [Reference Citation Analysis]
29 Amir M, Zeng MY. Immune imprinting in utero. Science 2021;373:967-8. [PMID: 34446596 DOI: 10.1126/science.abl3631] [Reference Citation Analysis]
30 Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E. Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report. Sultan Qaboos Univ Med J 2021;21:488-90. [PMID: 34522419 DOI: 10.18295/squmj.4.2021.021] [Reference Citation Analysis]
31 Ikeguchi R, Shimizu Y, Kondo A, Kanda N, So H, Kojima H, Kitagawa K. Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases. Neurol Neuroimmunol Neuroinflamm 2021;8:e1069. [PMID: 34429366 DOI: 10.1212/NXI.0000000000001069] [Reference Citation Analysis]
32 Tian M, Wang W, Wang K, Jin P, Lenahan C, Wang Y, Tan J, Wen H, Deng S, Zhao F, Gong Y. Dexmedetomidine alleviates cognitive impairment by reducing blood-brain barrier interruption and neuroinflammation via regulating Th1/Th2/Th17 polarization in an experimental sepsis model of mice. Int Immunopharmacol 2021;:108332. [PMID: 34785141 DOI: 10.1016/j.intimp.2021.108332] [Reference Citation Analysis]
33 Zhang J, Bouch RJ, Blekhman MG, He Z. USP19 Suppresses Th17-Driven Pathogenesis in Autoimmunity. J Immunol 2021:ji2100205. [PMID: 34135062 DOI: 10.4049/jimmunol.2100205] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Li Z, Liu Y, Jia A, Cui Y, Feng J. Cerebrospinal fluid cells immune landscape in multiple sclerosis. J Transl Med 2021;19:125. [PMID: 33766068 DOI: 10.1186/s12967-021-02804-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Fischer S, Proschmann U, Akgün K, Ziemssen T. Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells 2021;10:3177. [PMID: 34831400 DOI: 10.3390/cells10113177] [Reference Citation Analysis]
36 Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O'Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P. Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients. Front Immunol 2021;12:718895. [PMID: 34512642 DOI: 10.3389/fimmu.2021.718895] [Reference Citation Analysis]
37 Moser T, O'Sullivan C, Puttinger C, Feige J, Pilz G, Haschke-Becher E, Cadamuro J, Oberkofler H, Hitzl W, Harrer A, Kraus J, Trinka E, Wipfler P. Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy. Biomedicines 2021;9:1584. [PMID: 34829815 DOI: 10.3390/biomedicines9111584] [Reference Citation Analysis]